drugset / Trial / NCT01972763
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
Phase 1/2
Completed
12 enrolled
Northern California Retina Vitreous Associates
Genentech, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.
Timeline
- Start
- 2013-10
- Primary completion
- 2018-07
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | — |
| Comparator | Ranibizumab | Monoclonal antibody | 1 mg | — |